{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:33:03Z","timestamp":1771230783265,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12325-025-03394-2","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:08:31Z","timestamp":1761984511000},"page":"6295-6309","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter\u00a02 Inhibitor to Gliclazide-Based Therapy in Type\u00a02 Diabetes"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1561-2926","authenticated-orcid":false,"given":"Rodrigo O.","family":"Moreira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Nemencio A.","family":"Nicodemus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdurrahman","family":"Comlekci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mussa H.","family":"Almalki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"3394_CR1","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 11th edn. International Diabetes Federation, Brussels, Belgium, 2025."},{"issue":"1","key":"3394_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00125-024-06254-w","volume":"68","author":"K Khunti","year":"2025","unstructured":"Khunti K, Zaccardi F, Amod A, et al. Glycaemic control is still central in the hierarchy of priorities in type\u00a02 diabetes management. Diabetologia. 2025;68(1):17\u201328. https:\/\/doi.org\/10.1007\/s00125-024-06254-w.","journal-title":"Diabetologia"},{"key":"3394_CR3","doi-asserted-by":"publisher","unstructured":"International Diabetes Federation. IDF global clinical practice recommendations for managing type\u00a02 diabetes 2025. Diabetes Res Clin Pract. 2025. https:\/\/doi.org\/10.1016\/j.diabres.2025.112238.","DOI":"10.1016\/j.diabres.2025.112238"},{"issue":"7258","key":"3394_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type\u00a02 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312. https:\/\/doi.org\/10.1136\/bmj.321.7258.405.","journal-title":"BMJ"},{"issue":"10448","key":"3394_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","volume":"404","author":"AI Adler","year":"2024","unstructured":"Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type\u00a02 diabetes extended from 10\u00a0years to 24\u00a0years (UKPDS 91). Lancet. 2024;404(10448):145\u201355. https:\/\/doi.org\/10.1016\/S0140-6736(24)00537-3.","journal-title":"Lancet"},{"issue":"11","key":"3394_CR6","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","volume":"52","author":"FM Turnbull","year":"2009","unstructured":"Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type\u00a02 diabetes. Diabetologia. 2009;52(11):2288\u201398. https:\/\/doi.org\/10.1007\/s00125-009-1470-0.","journal-title":"Diabetologia"},{"issue":"4","key":"3394_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.therap.2021.10.002","volume":"77","author":"S Sun","year":"2022","unstructured":"Sun S, Hisland L, Grenet G, et al. Reappraisal of the efficacy of intensive glycaemic control on microvascular complications in patients with type\u00a02 diabetes: a meta-analysis of randomised control-trials. Therapie. 2022;77(4):413\u201323. https:\/\/doi.org\/10.1016\/j.therap.2021.10.002.","journal-title":"Therapie"},{"issue":"6","key":"3394_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","volume":"5","author":"S Zoungas","year":"2017","unstructured":"Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type\u00a02 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431\u20137. https:\/\/doi.org\/10.1016\/S2213-8587(17)30104-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"3394_CR9","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1111\/dom.15511","volume":"26","author":"SK Kunutsor","year":"2024","unstructured":"Kunutsor SK, Balasubramanian VG, Zaccardi F, et al. Glycaemic control and macrovascular and microvascular outcomes: a systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type\u00a02 diabetes. Diabetes Obes Metab. 2024;26(6):2069\u201381. https:\/\/doi.org\/10.1111\/dom.15511.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"3394_CR10","volume":"14","author":"SA Bin Rakhis Sr.","year":"2022","unstructured":"Bin Rakhis SA Sr., AlDuwayhis NM, Aleid N, AlBarrak AN, Aloraini AA. Glycemic control for type\u00a02 diabetes mellitus patients: a systematic review. Cureus. 2022;14(6):e26180.","journal-title":"Cureus"},{"key":"3394_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.diabres.2019.03.024","volume":"151","author":"MB Gomes","year":"2019","unstructured":"Gomes MB, Rathmann W, Charbonnel B, et al. Treatment of type\u00a02 diabetes mellitus worldwide: baseline patient characteristics in the global DISCOVER study. Diabetes Res Clin Pract. 2019;151:20\u201332. https:\/\/doi.org\/10.1016\/j.diabres.2019.03.024.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"3394_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/dom.13866","volume":"22","author":"K Khunti","year":"2020","unstructured":"Khunti K, Chen H, Cid-Ruzafa J, et al. Glycaemic control in patients with type\u00a02 diabetes initiating second-line therapy: results from the global DISCOVER study programme. Diabetes Obes Metab. 2020;22(1):66\u201378. https:\/\/doi.org\/10.1111\/dom.13866.","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"3394_CR13","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.2024.28513","volume":"333","author":"K Inoue","year":"2025","unstructured":"Inoue K, Liu M, Aggarwal R, Marinacci L, Wadhra RK. Prevalence and control of diabetes among US adults, 2013 to 2023. JAMA. 2025;333(14):1255\u20137. https:\/\/doi.org\/10.1001\/jama.2024.28513.","journal-title":"JAMA"},{"issue":"suppl 1","key":"3394_CR14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.2337\/dc24-SINT","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes 2025. Diabetes Care. 2024;48(suppl 1):S1\u2013343.","journal-title":"Diabetes Care"},{"issue":"11","key":"3394_CR15","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type\u00a02 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386. https:\/\/doi.org\/10.2337\/dci22-0034.","journal-title":"Diabetes Care"},{"issue":"11","key":"3394_CR16","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s13300-020-00926-7","volume":"11","author":"D Matthews","year":"2020","unstructured":"Matthews D, Del Prato S, Mohan V, et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type\u00a02 diabetes. Diabetes Ther. 2020;11(11):2465\u201376. https:\/\/doi.org\/10.1007\/s13300-020-00926-7.","journal-title":"Diabetes Ther"},{"issue":"Suppl 3","key":"3394_CR17","doi-asserted-by":"publisher","first-page":"S368","DOI":"10.2337\/diabetes.51.2007.s368","volume":"51","author":"P Proks","year":"2002","unstructured":"Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51(Suppl 3):S368\u201376. https:\/\/doi.org\/10.2337\/diabetes.51.2007.s368.","journal-title":"Diabetes"},{"issue":"2","key":"3394_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","volume":"5","author":"S Kalra","year":"2014","unstructured":"Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther. 2014;5(2):355\u201366. https:\/\/doi.org\/10.1007\/s13300-014-0089-4.","journal-title":"Diabetes Ther"},{"issue":"8","key":"3394_CR19","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2337\/dc18-0588","volume":"41","author":"MJB van Baar","year":"2018","unstructured":"van Baar MJB, van Ruiten CC, Muskiet MHA, van Bloemendaal L, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type\u00a02 diabetes management. Diabetes Care. 2018;41(8):1543\u201356. https:\/\/doi.org\/10.2337\/dc18-0588.","journal-title":"Diabetes Care"},{"issue":"39","key":"3394_CR20","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192.","journal-title":"Eur Heart J"},{"issue":"4S","key":"3394_CR21","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018.","journal-title":"Kidney Int"},{"issue":"7","key":"3394_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S2213-8587(24)00102-5","volume":"12","author":"MS Usman","year":"2024","unstructured":"Usman MS, Bhatt DL, Hameed I, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12(7):447\u201361. https:\/\/doi.org\/10.1016\/S2213-8587(24)00102-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"3394_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","volume":"143","author":"MMY Lee","year":"2021","unstructured":"Lee MMY, Brooksbank KJM, Wetherall K, et al. Effect of empagliflozin on left ventricular volumes in patients with type\u00a02 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF). Circulation. 2021;143(6):516\u201325. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052186.","journal-title":"Circulation"},{"issue":"8","key":"3394_CR24","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0005","volume":"12","author":"MC Thomas","year":"2023","unstructured":"Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type\u00a02 diabetes and CKD: a narrative review. Endocr Connect. 2023;12(8):e230005. https:\/\/doi.org\/10.1530\/EC-23-0005.","journal-title":"Endocr Connect"},{"issue":"4","key":"3394_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2213-8587(23)00065-7","volume":"11","author":"S Del Prato","year":"2023","unstructured":"Del Prato S. The growing clinical effect of SGLT2 inhibitors. Lancet Diabetes Endocrinol. 2023;11(4):218\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(23)00065-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"3394_CR26","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1161\/CIRCULATIONAHA.124.069568","volume":"149","author":"SM Patel","year":"2024","unstructured":"Patel SM, Kang YM, Im K, et al. Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis. Circulation. 2024;149(23):1789\u2013801. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069568.","journal-title":"Circulation"},{"issue":"7","key":"3394_CR27","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s13300-022-01280-6","volume":"13","author":"JM Gonz\u00e1lez-Clemente","year":"2022","unstructured":"Gonz\u00e1lez-Clemente JM, Garc\u00eda-Castillo M, Gorgojo-Mart\u00ednez JJ, et al. Beyond the glycaemic control of dapagliflozin: impact on arterial stiffness and macroangiopathy. Diabetes Ther. 2022;13(7):1281\u201398. https:\/\/doi.org\/10.1007\/s13300-022-01280-6.","journal-title":"Diabetes Ther"},{"issue":"5","key":"3394_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1177\/1479164115585298","volume":"12","author":"CD Sj\u00f6str\u00f6m","year":"2015","unstructured":"Sj\u00f6str\u00f6m CD, Johansson P, Ptaszynska A, List J, Johnsson E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type\u00a02 diabetes. Diabetes Vasc Dis Res. 2015;12(5):352\u20138. https:\/\/doi.org\/10.1177\/1479164115585298.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"3","key":"3394_CR29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S2213-8587(15)00417-9","volume":"4","author":"MA Weber","year":"2016","unstructured":"Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type\u00a02 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase\u00a03 study. Lancet Diabetes Endocrinol. 2016;4(3):211\u201320. https:\/\/doi.org\/10.1016\/S2213-8587(15)00417-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"3394_CR30","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"21","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;21(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"issue":"5","key":"3394_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","volume":"2","author":"JJV McMurray","year":"2021","unstructured":"McMurray JJV, Wheeler DC, Stef\u00e1nsson BV, et al. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease. Circulation. 2021;2(5):438\u201348. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.051675.","journal-title":"Circulation"},{"issue":"2","key":"3394_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","volume":"141","author":"MN Kosiborod","year":"2020","unstructured":"Kosiborod MN, Jhund PS, Docherty KF, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation. 2020;141(2):90\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044138.","journal-title":"Circulation"},{"issue":"7","key":"3394_CR33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ejhf.2909","volume":"25","author":"AS Bhatt","year":"2023","unstructured":"Bhatt AS, Kosiborod MN, Vaduganathan M, et al. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: participant-level pooled analysis from the DAPA-HF and DELIVER trials. Eur J Heart Fail. 2023;25(7):981\u20138. https:\/\/doi.org\/10.1002\/ejhf.2909.","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"3394_CR34","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"10","key":"3394_CR35","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.2337\/dc22-0382","volume":"1","author":"O Mosenzon","year":"2022","unstructured":"Mosenzon O, Raz I, Wiviott SD, et al. Dapagliflozin and prevention of kidney disease among patients with type\u00a02 diabetes: post hoc analyses from the DECLARE-TIMI\u00a058 trial. Diabetes Care. 2022;1(10):2350\u20139. https:\/\/doi.org\/10.2337\/dc22-0382.","journal-title":"Diabetes Care"},{"issue":"8","key":"3394_CR36","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type\u00a02 diabetes: an analysis from the DECLARE-TIMI\u00a058 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606\u201317. https:\/\/doi.org\/10.1016\/S2213-8587(19)30180-9.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3394_CR37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"issue":"8","key":"3394_CR38","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/dom.12666","volume":"18","author":"LA Leiter","year":"2016","unstructured":"Leiter LA, Cefalu WT, de Bruin TW, et al. Long-term maintenance of efficacy of dapagliflozin in patients with type\u00a02 diabetes mellitus and cardiovascular disease. Diabetes Obes Metab. 2016;18(8):766\u201374. https:\/\/doi.org\/10.1111\/dom.12666.","journal-title":"Diabetes Obes Metab"},{"issue":"19","key":"3394_CR39","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.jacc.2022.08.745","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Claggett B, Jhund P, et al. Estimated long-term benefit of dapagliflozin in patients with heart failure. J Am Coll Cardiol. 2022;80(19):1775\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3394_CR40","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(23)00009-8","volume":"11","author":"M Schechter","year":"2023","unstructured":"Schechter M, Wiviott SD, Raz I, et al. Effects of dapagliflozin on hospitalisations in people with type\u00a02 diabetes: post-hoc analyses of the DECLARE-TIMI\u00a058 trial. Lancet Diabetes Endocrinol. 2023;11(4):233\u201341. https:\/\/doi.org\/10.1016\/S2213-8587(23)00009-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"3394_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202563","volume":"13","author":"D Qian","year":"2018","unstructured":"Qian D, Zhang T, Tan X, et al. Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type\u00a02 diabetes mellitus: a network meta-analysis. PLoS ONE. 2018;13(8):e0202563. https:\/\/doi.org\/10.1371\/journal.pone.0202563.","journal-title":"PLoS ONE"},{"issue":"22","key":"3394_CR42","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"26","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;26(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"1","key":"3394_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3711","volume":"40","author":"JTK Cheung","year":"2024","unstructured":"Cheung JTK, Yang A, Wu H, et al. Early treatment with dipeptidyl-peptidase\u00a04 inhibitors reduces glycaemic variability and delays insulin initiation in type\u00a02 diabetes: a propensity score-matched cohort study. Diabetes Metab Res Rev. 2024;40(1):e3711. https:\/\/doi.org\/10.1002\/dmrr.3711.","journal-title":"Diabetes Metab Res Rev"},{"issue":"11","key":"3394_CR44","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.2337\/dc16-1974","volume":"40","author":"SV Edelman","year":"2017","unstructured":"Edelman SV, Polonsky WH. Type\u00a02 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care. 2017;40(11):1425\u201332. https:\/\/doi.org\/10.2337\/dc16-1974.","journal-title":"Diabetes Care"},{"issue":"10","key":"3394_CR45","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","volume":"13","author":"K Strojek","year":"2011","unstructured":"Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type\u00a02 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928\u201338. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01434.x.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"3394_CR46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13300-015-0117-z","volume":"6","author":"G Fulcher","year":"2015","unstructured":"Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type\u00a02 diabetes mellitus: a randomized, controlled trial. Diabetes Ther. 2015;6(3):289\u2013302. https:\/\/doi.org\/10.1007\/s13300-015-0117-z.","journal-title":"Diabetes Ther"},{"issue":"11","key":"3394_CR47","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.2337\/dc12-2673","volume":"36","author":"HU H\u00e4ring","year":"2013","unstructured":"H\u00e4ring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type\u00a02 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36(11):3396\u2013404. https:\/\/doi.org\/10.2337\/dc12-2673.","journal-title":"Diabetes Care"},{"key":"3394_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0260-x","volume":"14","author":"SK Paul","year":"2015","unstructured":"Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type\u00a02 diabetes. Cardiovasc Diabetol. 2015;14:100. https:\/\/doi.org\/10.1186\/s12933-015-0260-x.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"3394_CR49","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2337\/ds22-0084","volume":"36","author":"JR Gavin","year":"2023","unstructured":"Gavin JR, Abaniel RM, Virdi NS. Therapeutic inertia and delays in insulin intensification in type\u00a02 diabetes: a literature review. Diabetes Spectr. 2023;36(4):379\u201384. https:\/\/doi.org\/10.2337\/ds22-0084.","journal-title":"Diabetes Spectr"},{"issue":"6","key":"3394_CR50","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.diabet.2017.06.003","volume":"43","author":"G Reach","year":"2017","unstructured":"Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type\u00a02 diabetes mellitus. Diabetes Metab. 2017;43(6):501\u201311. https:\/\/doi.org\/10.1016\/j.diabet.2017.06.003.","journal-title":"Diabetes Metab"},{"issue":"9","key":"3394_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare10091673","volume":"10","author":"P Kaewbut","year":"2022","unstructured":"Kaewbut P, Kosachunhanun N, Phrommintikul A, Chinwong D, Hall JJ, Chinwong S. Time to treatment intensification to reduce diabetes-related complications: a post hoc study. Healthcare. 2022;10(9):1673. https:\/\/doi.org\/10.3390\/healthcare10091673.","journal-title":"Healthcare"},{"issue":"11","key":"3394_CR52","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s13300-020-00926-7","volume":"11","author":"D Matthews","year":"2020","unstructured":"Matthews D, Del Prato S, Mohan V, et al. Insights from VERIFY: early combination therapy provides better glycaemic durability than a stepwise approach in newly diagnosed type\u00a02 diabetes. Diabetes Ther. 2020;11(11):2465\u201376. https:\/\/doi.org\/10.1007\/s13300-020-00926-7.","journal-title":"Diabetes Ther"},{"issue":"2","key":"3394_CR53","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2337\/dc24-1516","volume":"48","author":"T Ohkuma","year":"2025","unstructured":"Ohkuma T, Harris K, Woodward M, et al. Intensive glucose lowering and its effects on vascular events and death according to age at diagnosis and duration of diabetes: the ADVANCE trial. Diabetes Care. 2025;48(2):279\u201384. https:\/\/doi.org\/10.2337\/dc24-1516.","journal-title":"Diabetes Care"},{"issue":"2","key":"3394_CR54","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.84353","volume":"17","author":"S Rabizadeh","year":"2019","unstructured":"Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review. Int J Endocrinol Metab. 2019;17(2):e84353. https:\/\/doi.org\/10.5812\/ijem.84353.","journal-title":"Int J Endocrinol Metab"},{"issue":"3","key":"3394_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/ehjcvp\/pvab056","volume":"8","author":"JS Aguilar-Gallardo","year":"2022","unstructured":"Aguilar-Gallardo JS, Correa A, Contreras JP. Cardio-renal benefits of sodium-glucose co-transporter\u00a02 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2022;8(3):311\u201321. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab056.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"3394_CR56","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"1","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type\u00a02 diabetes: a meta-analysis. JAMA Cardiol. 2021;1(2):148\u201358. https:\/\/doi.org\/10.1001\/jamacardio.2020.4511.","journal-title":"JAMA Cardiol"},{"issue":"5","key":"3394_CR57","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","volume":"15","author":"S Seidu","year":"2024","unstructured":"Seidu S, Alabraba V, Davies S, et al. SGLT2 inhibitors\u2014the new standard of care for cardiovascular, renal and metabolic protection in type\u00a02 diabetes: a narrative review. Diabetes Ther. 2024;15(5):1099\u2013124. https:\/\/doi.org\/10.1007\/s13300-024-01550-5.","journal-title":"Diabetes Ther"},{"issue":"7","key":"3394_CR58","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"8","key":"3394_CR59","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","volume":"12","author":"EM Apperloo","year":"2024","unstructured":"Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2024;12(8):545\u201357. https:\/\/doi.org\/10.1016\/S2213-8587(24)00155-4.","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03394-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:04:05Z","timestamp":1763132645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03394-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3394"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03394-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rodrigo Moreira: Fees as speaker from Servier, Novo Nordisk, AstraZeneca, Bayer, Eli Lilly. Nemencio A Nicodemus Jr.: Speaker honoraria from Servier, AstraZeneca, Boehringer Ingelheim and Taisho. Abdurrahman Comlekci: No conflict of interest. Miao Yu: Honoraria for speaker engagement from MSD, Novo Nordisk, Sanofi, Eli Lilly, Novartis, Servier and AstraZeneca; has served on Advisory boards for Novo Nordisk, Sanofi, MSD, Eli Lilly, Roche and AstraZeneca. Mussa H Almalki: No conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. Ethics approval was received from appropriate committees in each of the countries where the study was conducted, representing all the sites that were included (Supplementary Table\u00a0\n                      \n                      ). Informed consent for medical record review and the use of research-related health information was obtained in accordance with local regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}